UPS responds to growing demand from biopharmaceutical manufacturers
UPS has expanded its International Special Commodities (ISC) programme to more than 20 additional international destinations. This means that customers in more than 50 nations can ship biological substances, dangerous goods in excepted quantities and shipments utilising dry ice via UPS. The expansion is a direct response to a growing demand from biopharmaceutical manufacturers, diagnostics companies, laboratories and distributors to ship these specialised commodities when security, time and temperature control are a high priority.
“The UPS global transportation network has been enhanced to move biological specimens to and from more than 50 countries around the world,” said John Menna, UPS vice president of global strategy, healthcare logistics. “The expanded programme was guided by our customers to include the locations that are most important to them.”
UPS is now able to pick up and deliver packages under regulation UN3373 (Biologic Substances, Category B, Diagnostic Specimen and Clinical Specimen) as well as UN1845 (Carbon Dioxide, solid or dry ice) in Australia, Bulgaria, Croatia, Estonia, India, Indonesia, Israel, Latvia, Lithuania, New Zealand, Panama, Romania, Russia*, Saudi Arabia*, Slovakia, Slovenia, South Africa, Taiwan, Turkey and Ukraine.
Healthcare and life science companies shipping high-value, time- and temperature-sensitive shipments to, from and within the U.S. and key European markets, also have access to UPS Proactive Response® Secure – a solution combining shipment monitoring and risk management to mitigate product spoilage. The service helps critical shipments reach their destinations even if unexpected events occur and covers potential losses if products are damaged or spoiled.
